Regulatory roles of noncanonical inflammasomes in kidney diseases

IF 4.8 2区医学 Q2 IMMUNOLOGY

International immunopharmacology Pub Date : 2025-05-03 DOI:10.1016/j.intimp.2025.114787

Young-Su Yi

{"title":"Regulatory roles of noncanonical inflammasomes in kidney diseases","authors":"Young-Su Yi","doi":"10.1016/j.intimp.2025.114787","DOIUrl":null,"url":null,"abstract":"<div><div>Inflammation is a body's immune defense against infection and injury. The inflammatory response has two main phases: the priming and triggering phases. The triggering phase involves the activation of inflammasomes, cytoplasmic platforms for initiating inflammation, and Inflammasomes are classified into two categories: canonical and noncanonical. Kidney disease, or renal disease, refers to damage or illness affecting the kidneys, leading to a progressive decline in their function. Although the roles of canonical inflammasomes in kidney diseases are well-documented, recent research highlights novel roles of noncanonical inflammasomes in managing various inflammatory conditions. In particular, emerging studies emphasize the regulatory functions of noncanonical inflammasomes in a range of kidney diseases. This review explores recent discoveries regarding the regulatory functions of noncanonical inflammasomes, including human caspase-4/5 and murine caspase-11, in the progression of kidney diseases. It also examines the potential of targeting these inflammasomes as a novel therapeutic approach.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"157 ","pages":"Article 114787"},"PeriodicalIF":4.8000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925007775","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Inflammation is a body's immune defense against infection and injury. The inflammatory response has two main phases: the priming and triggering phases. The triggering phase involves the activation of inflammasomes, cytoplasmic platforms for initiating inflammation, and Inflammasomes are classified into two categories: canonical and noncanonical. Kidney disease, or renal disease, refers to damage or illness affecting the kidneys, leading to a progressive decline in their function. Although the roles of canonical inflammasomes in kidney diseases are well-documented, recent research highlights novel roles of noncanonical inflammasomes in managing various inflammatory conditions. In particular, emerging studies emphasize the regulatory functions of noncanonical inflammasomes in a range of kidney diseases. This review explores recent discoveries regarding the regulatory functions of noncanonical inflammasomes, including human caspase-4/5 and murine caspase-11, in the progression of kidney diseases. It also examines the potential of targeting these inflammasomes as a novel therapeutic approach.

Abstract Image

查看原文本刊更多论文

非典型炎性小体在肾脏疾病中的调节作用

炎症是机体对感染和损伤的免疫防御。炎症反应有两个主要阶段：启动阶段和触发阶段。触发阶段涉及炎性小体的激活，即启动炎症的细胞质平台，炎性小体分为两类：典型和非典型。肾脏疾病是指影响肾脏的损害或疾病，导致其功能逐渐下降。尽管典型炎症小体在肾脏疾病中的作用已被充分证明，但最近的研究强调了非典型炎症小体在各种炎症条件下的新作用。特别是，新兴的研究强调了非典型炎症小体在一系列肾脏疾病中的调节功能。本文综述了非典型炎性小体（包括人caspase-4/5和鼠caspase-11）在肾脏疾病进展中的调节功能的最新发现。它还研究了靶向这些炎性小体作为一种新的治疗方法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.